131 related articles for article (PubMed ID: 31532265)
21. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
[TBL] [Abstract][Full Text] [Related]
22. Predicting Endoscopic Crohn's Disease Activity Before and After Induction Therapy in Children: A Comprehensive Assessment of PCDAI, CRP, and Fecal Calprotectin.
Zubin G; Peter L
Inflamm Bowel Dis; 2015 Jun; 21(6):1386-91. PubMed ID: 25851564
[TBL] [Abstract][Full Text] [Related]
23. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score.
Bodelier AG; Jonkers D; van den Heuvel T; de Boer E; Hameeteman W; Masclee AA; Pierik MJ
Dig Dis Sci; 2017 Feb; 62(2):465-472. PubMed ID: 27933473
[TBL] [Abstract][Full Text] [Related]
24. Fecal calprotectin in the prediction of postoperative recurrence of Crohn's disease in children and adolescents.
Hukkinen M; Pakarinen MP; Merras-Salmio L; Koivusalo A; Rintala R; Kolho KL
J Pediatr Surg; 2016 Sep; 51(9):1467-72. PubMed ID: 26891835
[TBL] [Abstract][Full Text] [Related]
25. Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission.
Diederen K; Hoekman DR; Leek A; Wolters VM; Hummel TZ; de Meij TG; Koot BG; Tabbers MM; Benninga MA; Kindermann A
Aliment Pharmacol Ther; 2017 Apr; 45(7):951-960. PubMed ID: 28138990
[TBL] [Abstract][Full Text] [Related]
26. Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity.
Schaffer T; Schoepfer AM; Seibold F;
J Crohns Colitis; 2014 Sep; 8(9):1125-32. PubMed ID: 24636141
[TBL] [Abstract][Full Text] [Related]
27. Variation of faecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn's disease.
Boube M; Laharie D; Nancey S; Hebuterne X; Fumery M; Pariente B; Roblin X; Peyrin-Biroulet L; Minet-Quinard R; Pereira B; Bommelaer G; Buisson A;
Dig Liver Dis; 2020 Jul; 52(7):740-744. PubMed ID: 32444250
[TBL] [Abstract][Full Text] [Related]
28. Low fecal calprotectin predicts clinical remission in Crohn's disease patients: the simple answer to a challenging question.
Monteiro S; Dias de Castro F; Leite S; Moreira MJ; Cotter J
Scand J Gastroenterol; 2019 Jan; 54(1):49-54. PubMed ID: 30663515
[TBL] [Abstract][Full Text] [Related]
29. Correlation between fecal calprotectin and inflammation in the surgical specimen of Crohn's disease.
Pous-Serrano S; Frasson M; Cerrillo E; Beltrán B; Iborra M; Hervás D; García-Granero E; Nos P
J Surg Res; 2017 Jun; 213():290-297. PubMed ID: 28601328
[TBL] [Abstract][Full Text] [Related]
30. Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy.
Ferreiro-Iglesias R; Barreiro-de Acosta M; Otero Santiago M; Lorenzo Gonzalez A; Alonso de la Peña C; Benitez Estevez AJ; Dominguez-Muñoz JE
J Clin Gastroenterol; 2016 Feb; 50(2):147-51. PubMed ID: 25811118
[TBL] [Abstract][Full Text] [Related]
31. Fecal calprotectin is a strong predictive marker of relapse in Chinese patients with Crohn's disease: a two-year prospective study.
Ye L; Chen BQ; Wang SD; Shi H; Yang Z; Wang FY
Scand J Gastroenterol; 2017 Oct; 52(10):1113-1119. PubMed ID: 28675068
[TBL] [Abstract][Full Text] [Related]
32. Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn's Disease.
Plevris N; Fulforth J; Lyons M; Siakavellas SI; Jenkinson PW; Chuah CS; Lucaciu L; Pattenden RJ; Arnott ID; Jones GR; Lees CW
Clin Gastroenterol Hepatol; 2021 Sep; 19(9):1835-1844.e6. PubMed ID: 32798706
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Fecal Inflammatory Markers in Crohn's Disease.
Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Keenan JI; Leach S; Burgess L; Aitchison A; Gorelik A; Liew D; Day AS; Gearry RB
Inflamm Bowel Dis; 2016 May; 22(5):1086-94. PubMed ID: 26818420
[TBL] [Abstract][Full Text] [Related]
34. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment.
Sipponen T; Björkesten CG; Färkkilä M; Nuutinen H; Savilahti E; Kolho KL
Scand J Gastroenterol; 2010 Mar; 45(3):325-31. PubMed ID: 20034360
[TBL] [Abstract][Full Text] [Related]
35. The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease.
Zhulina Y; Cao Y; Amcoff K; Carlson M; Tysk C; Halfvarson J
Aliment Pharmacol Ther; 2016 Sep; 44(5):495-504. PubMed ID: 27402063
[TBL] [Abstract][Full Text] [Related]
36. Serum calprotectin as a biomarker for Crohn's disease.
Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
[TBL] [Abstract][Full Text] [Related]
37. Fecal calprotectin is significantly linked to azathioprine metabolite concentrations in Crohn's disease.
Essmann J; Keil C; Unruh O; Otte A; Manns MP; Bachmann O
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):99-108. PubMed ID: 30212402
[TBL] [Abstract][Full Text] [Related]
38. Fecal Calprotectin in Ileal Crohn's Disease: Relationship with Magnetic Resonance Enterography and a Pathology Score.
Cerrillo E; Beltrán B; Pous S; Echarri A; Gallego JC; Iborra M; Pamies J; Nos P
Inflamm Bowel Dis; 2015 Jul; 21(7):1572-9. PubMed ID: 26052967
[TBL] [Abstract][Full Text] [Related]
39. Fecal calprotectin: a selection tool for small bowel capsule endoscopy in suspected IBD with prior negative bi-directional endoscopy.
Koulaouzidis A; Douglas S; Rogers MA; Arnott ID; Plevris JN
Scand J Gastroenterol; 2011 May; 46(5):561-6. PubMed ID: 21269246
[TBL] [Abstract][Full Text] [Related]
40. Limitations of fecal calprotectin at diagnosis in untreated pediatric Crohn's disease.
Shaoul R; Sladek M; Turner D; Paeregaard A; Veres G; Wauters GV; Escher J; Dias JA; Lionetti P; Staino A; Kolho KL; de Ridder L; Nuti F; Cucchiara S; Sheva O; Levine A;
Inflamm Bowel Dis; 2012 Aug; 18(8):1493-7. PubMed ID: 22275268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
